Progressive interstitial lung disease associated with rheumatoid arthritis and abatacept: data from a multicentre cohort of 526 patients
Authors' conclusion
Despite ABA therapy, progressive ILD occurred in nearly one-quarter of RA patients.
Study context
- Population
- RA-associated interstitial lung disease (ILD) patients treated with abatacept in clinical practice, with serial pulmonary function testsfrom cohort of 526
- Participants
- 343 patients
- Exposure
- Progressive vs stable or improved ILD in RA-ILD treated with abatacept
- Progressive ILDn = 80
- Stable or improvedn = 263reference
- Outcome
- Progressive ILD (absolute decline in FVC ≥10% or relative decline of 5-9% with clinical and/or radiological progression)
- Follow-up
- 24 months after starting ABA
Methodological detailsnational multicentre, multivariable analysis
- National multicentre
- Multivariable analysis
Main finding
As reported in the abstract
Progressive ILD · 24 months
Observational data: associations, not effects.
Further findings
Prior MTX exposure, progressive ILD vs stable or improved
- Prior MTX exposure, progressive cases vs stable/improved (p = 0.02)
- 63% vs 76%
- Lower prior exposure among progressive cases
Prior tocilizumab exposure, progressive ILD vs stable or improved
- Prior tocilizumab exposure, progressive cases vs stable/improved (p = 0.048)
- 4 vs 34
- Lower prior exposure among progressive cases
Predictors of ILD progression (multivariable analysis)
- Prior MTX treatment (protective), OR
- 0.453
- Previous golimumab exposure, OR
- 10.009
- Higher DAS28-ESR, OR
- 1.284
- Multivariable analysis
ILD progression by ILD radiologic pattern or time from ABA initiation
- No significant differences according to ILD radiologic pattern or time from ABA initiation
Original publication
Progressive interstitial lung disease associated with rheumatoid arthritis and abatacept: data from a multicentre cohort of 526 patients. Rheumatology (Oxford). Published 18 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →